Panel Discussion: From Signal to Strategy: How Liquid Biopsy is Rewriting Drug Development Decisions
- Turning ctDNA and MRD signals into faster, higher confidence go/no-go decisions across modalities
- Cutting years and cost from development by replacing slow endpoints with early molecular insight
- Making liquid biopsy work in the real world: global logistics, scalability, and ROI for sponsors